(Q39084498)

8 September 2017

title

MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma (English)

1 reference

8 September 2017

1 reference

1 reference

Z-X Yan

1

1 reference

8 September 2017

L-L Wu

2

1 reference

8 September 2017

K Xue

3

1 reference

8 September 2017

Q-L Zhang

4

1 reference

8 September 2017

Y Guo

5

1 reference

8 September 2017

M Romero

6

1 reference

8 September 2017

C Leboeuf

7

1 reference

8 September 2017

A Janin

8

1 reference

8 September 2017

S-J Chen

9

1 reference

8 September 2017

L Wang

10

1 reference

8 September 2017

W-L Zhao

11

1 reference

8 September 2017

publication date

9 October 2013

1 reference

8 September 2017

1 reference

8 September 2017

volume

28

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

880-887

1 reference

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

TCR-dependent transformation of mature memory phenotype T cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Myc proteins as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

MicroRNA-target interactions: new insights from genome-wide approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.291

Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24104394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24104394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The life cycle of C-myc: from synthesis to degradation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24104394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.291

1 reference

Dimensions Publication ID

8 September 2017

1018295553

0 references

1 reference